Higher IL-6 and IL6:IGF ratio in patients with barth syndrome

Journal of Inflammation (United Kingdom)

Volumn 9, Issue , 2012, Pages

  Wilson, Lori D ^a,d   Al Majid, Sadeeka ^b   Rakovski, Cyril S ^c   Md, Christina D Schwindt ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

^c CHAPMAN UNIVERSITY   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

^e Southern California Research   (United States)

Author keywords

cardiolipin; catabolic; dilated cardiac myopathy; inflammation; mitochondria; Myopathy

Indexed keywords

GROWTH HORMONE; INTERLEUKIN 6; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ANALYTICAL PARAMETERS; ARTICLE; BARTH SYNDROME; BIOSYNTHESIS; CATABOLISM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE DYSREGULATION; INFANT; INTERLEUKIN 6 SOMATOMEDIN RATIO; MALE; PROTEIN BLOOD LEVEL; SCHOOL CHILD; TUMOR NECROSIS FACTOR GROWTH HORMONE RATIO; UPREGULATION;

EID: 84862487772     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-9-25     Document Type: Article

References (29)

1. Little known killer: Barth syndrome. Bateman C, S Afr Med J 2003 93 249 250 12806708
2. Sepsis-induced suppression of skeletal muscle translation initiation mediated by tumor necrosis factor alpha. Lang CH, Frost RA, Metabolism 2007 56 49 57 10.1016/j.metabol.2006.08.025 17161226
3. Acute treatment with tumour necrosis factor-alpha induces changes in protein metabolism in rat skeletal muscle. Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM, Mol Cell Biochem 1993 125 11 18 10.1007/BF00926829 8264567
4. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Janssen SP, Gayan-Ramirez G, Van den Bergh A, Herijgers P, Maes K, Verbeken E, Decramer M, Circulation 2005 111 996 1005 10.1161/01.CIR.0000156469. 96135.0D 15710765
5. Regulation of muscle protein synthesis during sepsis and inflammation. Lang CH, Frost RA, Vary TC, Am J Physiol Endocrinol Metab 2007 293 453 459 10.1152/ajpendo.00204.2007 17505052
6. Insulin-like growth factor I accelerates protein synthesis in skeletal muscle during sepsis. Jurasinski CV, Vary TC, Am J Physiol 1995 269 977 981 7491951
7. Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle. Grounds MD, Radley HG, Gebski BL, Bogoyevitch MA, Shavlakadze T, Clin Exp Pharmacol Physiol 2008 35 846 851 10.1111/j.1440-1681.2007.04868.x 18215180
8. Significance of interleukin-6 in patients with inflammatory bowel disease. Mitsuyama K, Sata M, Tanikawa K, Gastroenterol Jpn 1991 26 20 28 2007457
9. Osteoporosis and inflammation. Lacativa PG, Farias ML, Arq Bras Endocrinol Metabol 54 123 132
10. R Development Core Team RFfSC, R: A language and environment for statistical computing 2008
11. Do surrogate markers for adiposity relate to cytokines in adolescents? Rubin DA, McMurray RG, Harrell JS, Hackney AC, Haqq AM, J Investig Med 2008 56 786 792 18525454
12. Eliakim A, Nussbaum E, Dunton G, Leu SY, Cooper DM, Schneider M: Physical activity, growth, and inflammatory mediators in BMI-matched female adolescents. Ischander M, Zaldivar F, Med Sci Sports Exerc 2007 39 1131 1138 10.1249/mss.0b013e318053e7a2 17596781
13. Resting and exercise-induced IL-6 levels in children with Type 1 diabetes reflect hyperglycemic profiles during the previous 3days. Rosa JS, Flores RL, Oliver SR, Pontello AM, Zaldivar FP, Galassetti PR, J Appl Physiol 108 334 342
14. Testosterone effect on growth and growth mediators of the GH-IGF-I axis in the liver and epiphyseal growth plate of juvenile rats. Zung A, Phillip M, Chalew SA, Palese T, Kowarski AA, Zadik Z, J Mol Endocrinol 1999 23 209 221 10.1677/jme.0.0230209 10514558
15. Prediction of the outcome of growth hormone provocative testing in short children by measurement of serum levels of insulin-like growth factor I and insulin-like growth factor binding protein 3. Juul A, Skakkebaek NE, J Pediatr 1997 130 197 204 10.1016/S0022-3476(97)70343-3 9042120
16. Association between height, BMI and blood levels of IGF-I, IGFBP-1, IGFBP-2 and IGFBP-3. Crowe FL KT, Allen NE, Appleby PN, Overvad K, Grønbæk H, Tjønneland A, Halkjær J, Dossus L, Boeing H, Kröger J, Trichopoulou A, Zylis D, Trichopoulos D, Boutron-Ruault MC, de Lauzon-Guillain B, Clavel-Chapelon F, Palli D, Berrino F, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Gram IT, Rodríguez L, Jakszyn P, Molina-Montes E, Navarro C, Barricarte A, Larrãaga N, Khaw KT, Rodwell S, Rinaldi S, Slimani N, Norat T, Gallo V, Riboli E, Kaaks R, Annu Hum Biol 2010
17. Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise. Bodell PW, Kodesh E, Haddad F, Zaldivar FP, Cooper DM, Adams GR, J Appl Physiol 2009 106 443 453 19057004
18. Role of IGF signaling in catch-up growth and accelerated temporal development in zebrafish embryos in response to oxygen availability. Kamei H, Ding Y, Kajimura S, Wells M, Chiang P, Duan C, Development 2011 138 777 786 10.1242/dev.056853 21266413
19. Upregulation of IL-6 mRNA by IL-6 in skeletal muscle cells: role of IL-6 mRNA stabilization and Ca2+dependent mechanisms. Weigert C, Dufer M, Simon P, Debre E, Runge H, Brodbeck K, Haring HU, Schleicher ED, Am J Physiol Cell Physiol 2007 293 1139 1147 10.1152/ajpcell.00142.2007 17615159
20. IL-6 signalling in exercise and disease. Pedersen BK, Biochem Soc Trans 2007 35 1295 1297 17956334
21. Insulin-like growth factor I signaling in skeletal muscle and the potential for cytokine interactions. Adams GR, Med Sci Sports Exerc 2010 42 50 57 20010130
22. Hypoxia converts the myogenic action of insulin-like growth factors into mitogenic action by differentially regulating multiple signaling pathways. Ren H, Accili D, Duan C, Proc Natl Acad Sci U S A 2010 107 5857 5862 10.1073/pnas.0909570107 20231451
23. Nuclear translocation and retention of growth hormone. Mertani HC, Raccurt M, Abbate A, Kindblom J, Tornell J, Billestrup N, Usson Y, Morel G, Lobie PE, Endocrinology 2003 144 3182 3195 10.1210/en.2002-221121 12810575
24. Growth hormone and liver mitochondria: time course of effects on respiration and fatty acid composition in hypophysectomized rats. Maddaiah VT, Clejan S, Endocrinology 1986 119 250 252 10.1210/endo-119-1-250 2941269
25. The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Savage MO, Burren CP, Rosenfeld RG, Clin Endocrinol (Oxf) 2010 72 721 728
26. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. Shavlakadze T, White J, Hoh JF, Rosenthal N, Grounds MD, Mol Ther 2004 10 829 843 10.1016/j.ymthe.2004.07.026 15509501
27. Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling. Grounds MD, Biogerontology 2002 3 19 24 10.1023/A:1015234709314 12014835
28. Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury. Davani EY, Brumme Z, Singhera GK, Cote HC, Harrigan PR, Dorscheid DR, Crit Care 2003 7 176 183 10.1186/cc2375 14624693
29. Age-dependent levels of select immunological mediators in sera of healthy children. Sack U, Burkhardt U, Borte M, Schadlich H, Berg K, Emmrich F, Clin Diagn Lab Immunol 1998 5 28 32 9455875